Articles

November 18, 2019 Building a Culture of Passion and Commitment Kelley Boucher, SVP/Chief Human Resources Officer, discusses Alnylam being named to The Boston Globe's 2019 Best Places to Work List... Read More ›
November 18, 2019 Alnylam Named a Boston Globe Top Place to Work for 5th Year in a Row We're thrilled to be named a Top Places to Work for 2019 by The Boston Globe in the "Large Employer" category, marking our fifth year in a row on the list.  Read More ›
November 5, 2019 A Truly Special Place for Science Recently, our company was named Science Magazine’s Top Employer for 2019 – a significant achievement in the scientific community and a true milestone... Read More ›
October 25, 2019 Alnylam Named #1 Biopharma Employer by Science Magazine Alnylam has been named the #1 science employer in biopharma for 2019 by Science Magazine and Science Careers. This is our first appearance on the list. Read More ›
October 1, 2019 The Importance of Ensuring Quality in a New Class of Medicines In Product Quality, we have a truly big picture view of the medicines we’re making to ensure they are compliant with good manufacturing practices and... Read More ›
October 1, 2019 Building for Our Future Why would a company without a commercially approved medicine decide to build a significant manufacturing facility? Why not continue to rely on contract... Read More ›
September 17, 2019 +MyFamily Program with 23andMe Aims to Increase Awareness of TTR-Related Hereditary Amyloi ... hATTR amyloidosis is a potentially devastating and life-threatening condition that may affect families, generation after generation. Read More ›
September 14, 2019 "Beyond the Visible" Art Exhibit Raises Awareness of Acute Hepatic Porphyria in Italy This past weekend, "Beyond the Visible," a first of its kind exhibition of original works of art created by a group of graphic design and art students... Read More ›
September 9, 2019 Alnylam's Patient Access Philosophy - Our Progress Nearly two years ago – before we launched our first product – we made a commitment to strive toward broad patient access to our medicines. In our view... Read More ›
September 2, 2019 ORION-11: A Landmark Event for RNAi Therapeutics The results from the ORION-11 Phase 3 study of inclisiran, presented earlier today at the European Society of Cardiology meeting represent a landmark event... Read More ›
Subscribe to Articles